SCHEMBL4408729

SCHEMBL4408729

CC1(C)NC(=O)N(CCC(=O)NN)C1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
POLB P06746 1/20 0.50
FPR2 P25090 1/20 0.45
APOBEC3A P31941 1/20 0.44
APOBEC3G Q9HC16 1/20 0.44
PADI4 Q9UM07 1/20 0.42
MEN1 O00255 2/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 3/20 0.40
PLA2G7 Q13093 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16256882 0.80 KMT2A (0.58) KMT2APOLBFPR2PADI4MEN1
SCHEMBL8165986 0.80 KMT2A (0.68) KMT2APOLBPADI4MEN1LMNA
SCHEMBL24568199 0.79 KMT2A (0.46) KMT2APOLBFPR2APOBEC3AAPOBEC3G
SCHEMBL24568599 0.77 KMT2A (0.44) KMT2APOLBFPR2APOBEC3AAPOBEC3G
SCHEMBL11967051 0.77 KMT2A (0.54) KMT2APOLBFPR2PADI4MEN1
SCHEMBL11677768 0.76 POLB (0.74) KMT2APOLBPADI4MEN1LMNA
SCHEMBL4410060 0.76 MAPT (0.37) KMT2APOLBLMNAPLA2G7
SCHEMBL8161187 0.76 APOBEC3A (0.43) KMT2APOLBFPR2APOBEC3AAPOBEC3G
SCHEMBL11955141 0.75 POLB (0.56) KMT2APOLBFPR2PADI4MEN1
SCHEMBL11826758 0.74 KMT2A (0.51) KMT2APOLBPADI4MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 US disclosed
US-7638565-B2 Polyacetal resin composition POLYPLASTICS CO., LTD. (JP) 2009-12-29 US disclosed
EP-2124913-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS Novartis AG (CH) 2009-12-02 EP disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 WO disclosed
US-20070054998-A1 Polyacetal resin composition POLYPLASTICS CO., LTD. (JP) 2007-03-08 US disclosed
EP-1686156-A1 POLYACETAL RESIN COMPOSITION Polyplastics Co., Ltd. (JP) 2006-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012485-A1 ORGANIC COMPOUNDS DPP4, DPP3, DPP7 KMT2A 2558/4885POLB 2463/4885FPR2 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.